Drugs / ALICAFORSEN SODIUM
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03473626 | Mar → Apr 2018 | inflammatory bowel disease | Atlantic Pharmaceuticals Ltd | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT00063830 | Apr 2003 → Oct 2004 | ulcerative colitis | Ionis Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00063414 | Nov 2002 → Mar 2005 | ulcerative colitis | Ionis Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT02525523 | Dec 2015 → Jul 2018 | pouchitis | Atlantic Pharmaceuticals Ltd | Completed | No outcome recorded |
| Phase 3 | NCT00048295 | May 2002 → ? | Crohn disease | Ionis Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00048113 | Jan 2001 → Apr 2002 | Crohn disease | Ionis Pharmaceuticals, Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 6
| Date | Issuer | Release |
|---|---|---|
| 2004-12-02 | Ionis Pharmaceuticals | Results Isis Pharmaceuticals Announces Results of Alicaforsen Phase 3 Clinical Trials in Patients With Crohn's Disease ionis.com ↗
Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today results of two Phase 3 trials that evaluated the first-generation antisense drug alicaforsen in patients with Crohn's disease. |
| 2004-12-02 | Ionis Pharmaceuticals | Results Alicaforsen Significantly Improves Symptoms and Produces Durable Responses in Patients With Ulcerative Colitis ionis.com ↗
Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today the results of three Phase 2 studies of alicaforsen enema to treat patients with ulcerative colitis (UC). |
| 2003-10-27 | Ionis Pharmaceuticals | Results Isis Pharmaceuticals Updates Positive Clinical Data on Multiple Antisense Drugs ionis.com ↗
Updated results of a Phase 2 study of alicaforsen (ISIS 2302) in patients with pouchitis were presented at the 67th Annual Scientific Meeting of the American College of Gastroenterology (ACG) |
| 2003-05-21 | Ionis Pharmaceuticals | Results Alicaforsen (ISIS 2302) Improves Clinical Symptoms of Pouchitis Patients ionis.com ↗
Patients with pouchitis experience an improvement in clinical disease symptoms after receiving treatment with alicaforsen (ISIS 2302), an antisense inhibitor of the inflammatory target Intercellular Adhesion Molecule-1 (ICAM-1), according to results of an open-label, uncontrolled Phase II clinical trial. |
| 2002-10-21 | Ionis Pharmaceuticals | Results Alicaforsen (ISIS 2302) Improves Potential for Responses and Remissions ionis.com ↗
Results of an open-label Phase II clinical trial of alicaforsen (ISIS 2302) in patients with Crohn's disease show that the antisense drug may produce clinical disease remissions when patients receive appropriate doses of the drug. |
| 2002-02-25 | Ionis Pharmaceuticals | Results Isis Pharmaceuticals Reports Phase II Study Results Of Topical Alicaforsen, ISIS 2302, in Psoriasis ionis.com ↗
In a Phase II clinical trial of patients with mild to moderate plaque psoriasis, a topical formulation of alicaforsen (ISIS 2302) demonstrated a statistically significant improvement in Investigator's Global Response Score (IGRS) at week four (p=0.02) and a positive trend toward improvement at week eight (p=0.206). |
All press releases naming this drug 9 releases
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALICAFORSEN SODIUM | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108895 ↗ |
| Known as | Alicaforsen | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00063414 ↗ |
| Known as | Alicaforsen nonadecasodium salt | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108895 ↗ |
| Known as | ISIS 2302 | “ISIS 2302-CS21, Phase 3 Double-Masked, Placebo-Controlled Study of Alicaforsen (ISIS 2302), an Antisense Inhibitor of ICAM-1, for the Treatment of Patients With Active Crohn's Disease” NCT00048295 ↗3“Alicaforsen (ISIS 2302), a new type of drug called an antisense drug” NCT00063414 ↗ “Alicaforsen (ISIS 2302)” NCT00048113 ↗ “Alicaforsen (ISIS 2302)” NCT00063830 ↗ |
| Action | Inhibit | “reduces the production of a specific protein called intercellular adhesion molecule (ICAM-1)” NCT00048295 ↗ |
| Route | Intravenous | “alicaforsen delivered by 2-hour intravenous infusion” NCT00048295 ↗ |
| Target | ICAM1 | “blocking ICAM-1 messenger RNA” NCT00048295 ↗ |